Floatz logo

COMBRESTATIN A4

Neuroendocrine Neoplasm

Mateon TherapeuticsSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Eloxatin
ITM Solucin GmbH
Phase 3BB
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Bms-907351
Fox Chase Cancer Center
Phase 3BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Surufatinib
Shanghai Changzheng Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

COMBRESTATIN A4 is also rated in:

ovarian cancerDormant
B
Indicative ·
57 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →